<?xml version='1.0' encoding='UTF-8'?><xml><records><record><source-app name="HighWire" version="7.x">Drupal-HighWire</source-app><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Nichols, Emma Hitt</style></author></authors><secondary-authors><author><style face="normal" font="default" size="100%">Ruff, Christian T.</style></author><author><style face="normal" font="default" size="100%">Shah, Rohan</style></author><author><style face="normal" font="default" size="100%">Alexander, John H.</style></author><author><style face="normal" font="default" size="100%">Bonde, Anders Nissen</style></author><author><style face="normal" font="default" size="100%">Le Heuzey, Jean-Yves</style></author></secondary-authors></contributors><titles><title><style face="normal" font="default" size="100%">NOACs</style></title><secondary-title><style face="normal" font="default" size="100%">MD Conference Express</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2015</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2015-11-09 11:22:16</style></date></pub-dates></dates><pages><style  face="normal" font="default" size="100%">13-15</style></pages><abstract><style  face="normal" font="default" size="100%">There are now 4 novel oral anticoagulants available as an alternative to vitamin K antagonists for the risk reduction of stroke and systemic embolism in patients with nonvalvular atrial fibrillation. However, many unanswered questions remain about their use in clinical practice, and numerous trials are ongoing.</style></abstract><number><style face="normal" font="default" size="100%">28 suppl 2</style></number><volume><style face="normal" font="default" size="100%">15</style></volume></record></records></xml>